Isofol Medical Q1’21: Our Comment

Redeye provides a short comment on the Q1 report and recent news flow, and the upcoming share issues.

NE

Niklas Elmhammer

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.